Clinical Trial Search

Primary: Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay — 4 participants

Primary: Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases — 150.8; 239.6 ratio

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Response Rate (Progression) for Patients With Glioblastoma That Have Progressed After Prior Treatment That Has Included Radiation, Temozolomide and Bevacizumab. — 6…

Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2

Primary: PSA Response, as Defined by ≥ 50% Decrease in PSA From Baseline — 1 Participants

Primary: Prostate Cancer Detection Within the Prostate Gland by Copper Cu 64 TP3805 PET — 25 Participants

Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants

Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05

Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…

Primary: Proportion of Subjects With a Demethylation Response at Each Dose Level — .22; .30 proportion of participants

Primary: Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging — 24 lesions

Primary: True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up

Primary: Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.) — 466; 102; 364; 235 participants

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Sensitivity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastases — .59; .89 proportion of participants

Primary: Number of Participants With a Positive Immune Response Following Vaccination Determined by Interferon (IFN) Gamma Enzyme-linked Immunosorbent Spot (ELISpot) — 12; 10…

Primary: Occurrence of Related Adverse Events - Grade 3 or Higher — 0; 0; 0 participants

Primary: PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA — 232; 27; 10; 24 participants

Primary: Number of Participants With > = Grade 2 Autoimmune Events or >=Toxicities at Least Possibly Related to pTVG-HP With GM-CSF Study Treatment. — 1; 0 participants

Primary: Number of Participants With Clinical Failure After Initiation of Radiotherapy — 315 Participants

Primary: Number of Prostate Cancer Diagnoses in MRI and no MRI Groups — 34; 34 participants

Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage

Primary: Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation — 0.90 percentage of times value is true

Primary: Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group — 0.38; 0.45; 0.76; 0.73 proportion

Primary: Percentage of Participants With Histologically Positive Lesions That Are Positive on Imaging — 86 % of participants with + lesions

Primary: Average SUVmax of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution — 12.4 SUVmax

Primary: Overall Time to Disease Progression — 10.9; 9.9 Weeks — p=0.719

Primary: Proportion of Patients With Lymph Node Involvement — 4; 28 Participants

Primary: Confirmation of Prostate Cancer Recurrence by 68Ga-PSMA-11 PET/CT — 46; 15 Participants